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Abstract
Introduction Adenocarcinoma in situ (AIS) of the
uterine cervix is the precursor to invasive endocervical
adenocarcinoma. An excisional biopsy such as a cold
knife cone biopsy (CKC) should be performed to exclude
invasive adenocarcinoma. Loop electrosurgical excision
procedure (LEEP) is an alternative modality to CKC but is
controversial in AIS. There is a perception that there is a
greater likelihood of incomplete excision of AIS with LEEP
because the depth of excised tissue tends to be smaller
and the tissue margins may show thermal artefact which
can interfere with pathology assessment. In the USA,
guidelines recommend that any treatment modality can
be used to excise AIS, provided that the specimen remains
intact with interpretable margins. However, there are no
high-quality studies comparing LEEP with CKC and welldesigned prospective studies are needed. If such a study
were to show that LEEP was non-inferior to CKC for the
outcomes of post-treatment persistence, recurrence and
adenocarcinoma, LEEP could be recommended as an
appropriate treatment option for AIS in selected patients.
This would benefit women because, unlike CKC, LEEP does
not require general anaesthesia and may be associated
with reduced morbidity.
Methods and analysis The proposed exploratory study
is a parallel group trial with an allocation ratio of 2:1
in favour of the intervention (LEEP: CKC). Participants
are women aged ≥18 to ≤45 years diagnosed with AIS
on cervical screening and/or colposcopically directed
biopsy in Australia and New Zealand, who are to receive
excisional treatment in a tertiary level centre.
Ethics and dissemination Ethical approval for the study
has been granted by the St John of God Healthcare Human
Research Ethics Committee (reference number #1137).

Strengths and limitations of the study
►► Strengths of this pilot study include its prospective,

randomised design, allocation concealment and
strategies to minimise surgical performance bias.
Should the pilot study demonstrate safety and
feasibility, potential limitations of a subsequent
phase III study include those pertaining to noninferiority trials which lack a placebo group, can only
provide an indirect assessment of the efficacy of the
treatment compared with an existing standard and
where the choice of non-inferiority margin can be
subjective.

Results from the study will be presented at conferences
and published in a peer-reviewed scientific journal.
Registration ANZCTR registration number
ACTRN12617000132347 https://www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=372173&isReview=true

Introduction
Adenocarcinoma in situ (AIS) of the uterine
cervix is the precursor to, and may coexist
with, invasive endocervical adenocarcinoma.1 Current guidelines recommend that
women in whom AIS is reported on screening
cytology are referred to a gynaecologist with
expertise in the colposcopic evaluation of
suspected malignancies or a gynaecologic
oncologist, and if invasive disease is not identified at colposcopy, a cold knife cone biopsy
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There are no prospective randomised studies of AIS
treatment to inform clinical practice. More recent retrospective studies have found similar recurrence and
persistence rates for LEEP and CKC.18 19 The absence of
prospective randomised studies has recently been highlighted by Cancer Council Australia’s working party draft
clinical management guidelines for the prevention of
cervical cancer.4 There is a clear need for prospective
randomised clinical trials to determine whether LEEP
is associated with similar histopathological and clinical
outcomes when compared with CKC in the investigation
and management of cervical AIS.
The Cancer Council Australia Cervical Cancer Screening
Guidelines Working Party argued that 'Well-designed
prospective research studies are needed to compare the
use of cold knife cone biopsy with diathermy loop excision
(LEEP or LLETZ) in the diagnosis and treatment of AIS. If
such a study were to show that loop excision was non-inferior
to cold-knife cone biopsy for the outcomes of post-treatment persistence and recurrence, and adenocarcinoma,
loop excision could be recommended as an appropriate
treatment option for AIS in selected patients. This would
benefit women because, unlike cold-knife cone procedures,
loop excision does not require hospital admission and
general anaesthesia. Studies evaluating endocervical curettage would provide useful evidence to determine its role in
clinical practice. Long-term data from the National Cervical
Screening Program should be analysed to determine the
minimal effective surveillance period for women undergoing annual Test of Cure for post-treatment AIS before
returning to routine 5-yearly screening’.4
The aim of the proposed pilot study is to demonstrate
the feasibility and safety of LEEP versus CKC for the
treatment of cervical AIS prior to conducting a phase III
prospective multicentre randomised non-inferiority trial.
The specific objectives of the proposed phase I study
are
1. to compare LEEP with CKC in terms of margin status
and specimen dimensions
2. to compare rates of early complications at 6 weeks,
for example, pain, infection, primary and secondary
haemorrhage, readmission to hospital, return to the
operating theatre after the two treatment modalities
3. to assess patient satisfaction following LEEP and CKC
4. to determine the costs of treatment.
If feasibility and safety are demonstrated, the objective
of the subsequent phase III trial would be to determine
if the treatment of cervical AIS by LEEP is non-inferior
to CKC in terms of disease persistence at 12 months and
recurrence at 5 years in women managed conservatively,
when treatment is performed in tertiary level dysplasia
and gynaecologic oncology centres.

Methods and analysis
The protocol conforms to the SPIRIT (Standard Protocol
Items for Randomised Trials) statement.
Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576
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(CKC) should be performed to exclude invasive adenocarcinoma.2 3
The role of alternative excision modalities to CKC in
the investigation and management of AIS has been the
subject of extensive debate. Single-specimen excision
biopsies with minimal thermal damage or disruption
of resection margins are essential for accurate histopathological assessment. A comprehensive review of the
Australian 2005 National Cervical Screening Programme
(NCSP) guidelines2 has recommended that ‘cold-knife
cone biopsy should be considered the "gold standard"
for the diagnostic assessment of glandular lesions.
However, a diathermy excisional procedure may be
appropriate in some circumstances and could provide
an appropriate surgical specimen when performed by
a gynaecologist with appropriate training, experience
and expertise’.4 There is a perception that there is a
greater likelihood of incomplete excision with loop
electrosurgical excision procedure (LEEP) because
the depth of excised tissue and the overall dimensions
of the specimen tend to be smaller in comparison to
CKC. It is also argued that the tissue margins in a LEEP
biopsy may show significant thermal artefact, which can
interfere with the pathological assessment of biopsy
margins.5 6 Some studies have shown a greater risk of a
positive endocervical margin with LEEP but these have
included cases in which AIS was not suspected prior to
the excisional procedure.7–9 However, current American Society for Colposcopy and Cervical Pathology
consensus guidelines recommend that any treatment
modality can be used for diagnostic excision, provided
that the specimen remains intact with interpretable
margins and that there is no fragmentation, including
‘top-hat’ serial endocervical excisions.3
Conservative treatment of women with AIS by CKC or
LEEP is also controversial because AIS may co-exist with
cervical adenocarcinoma10 and hence total hysterectomy
has been regarded as definitive management.3 However,
CKC and LEEP present fertility-preserving alternatives to
hysterectomy in women of reproductive age in whom AIS
is prevalent.11 12
Positive or close histopathological margins have been
associated with an increased risk of AIS persistence and
recurrence.13 A 2014 systematic review14 reported higher
rates of incomplete excision with LEEP (51%) than
with CKC (30%) or laser cone (28%) using pooled data
and reported rates of recurrence of AIS ranging from
9% to 29% after LEEP and from 6% to 11% after CKC.
This review concluded that LEEP had acceptable safety
and was comparable to CKC when negative margins
were achieved, and is associated with better obstetric
outcomes.14 Furthermore, recent evidence suggests that
CKC and LEEP are associated with similar rates of positive margins and recurrent AIS.15 Advantages of LEEP
compared with CKC include the ability to perform the
procedure under local anaesthesia in an outpatient
setting and lower morbidity, including adverse obstetric
outcomes.16 17

Open Access

Study setting
Academic tertiary level hospitals in Australia and New
Zealand.
Study sites are listed in the ANZCTR registration
number ACTRN12617000132347.
Web
address:
http://www.ANZCTR.org.au/
ACTRN12617000132347.aspx
Eligibility criteria
Women aged ≥18 to ≤45 years diagnosed with AIS on
cervical screening and/or colposcopically directed biopsy
in Australia and New Zealand, who are to receive excisional treatment in a tertiary level centre.
Inclusion criteria
►► Aged between ≥18 and 45 years of age at time of study
enrolment
►► Documentation of AIS on cervical cytology and/or
cervical biopsy test results
►► Lesion amenable to single-pass excision (serial endocervical excisions including ‘top-hat’ will not be
permitted in accordance with American Society for
Colposcopy and Cervical Pathology Recommendations)7
►► Proficient in English.
Exclusion criteria
►► High-grade cervical abnormality prior to current AIS
diagnosis
►► Previous excisional or ablative treatment (LEEP, CKC,
Fisher cone biopsy, laser cone, laser ablation, radical
diathermy)
►► Previous history of cervical cancer treated by radiation or chemoradiation
►► Cytology suspicious of invasion
►► Clinical/colposcopic suspicion of invasion
►► Presence of a concurrent gynaecological cancer
►► Patients unable to comply with follow-up evaluations
►► Immunosuppression
►► Pregnancy
►► Lesion considered unsuitable for single-pass excision
by treating specialist.
Interventions
Eligible participants will be randomised to undergo
either LEEP or CKC. LEEP is the standard procedure
performed for the more common high-grade squamous
cervical dysplasia and the technique is described in
detail in online supplementary appendix A. In Australia,
CKC has been the preferred technique to excise cervical
AIS and the technique is outlined in online supplementary appendix A. The interventions will be administered
within the usual clinical time frames as per local practice.
Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576

Patient management will follow the National Health
and Medical Research Council’s 2005 Screening to
prevent cervical cancer: guidelines for the management of
asymptomatic women with screen-detected abnormalities
and the revised 2016 guidelines. Participants randomised
to the LEEP arm of the study will have their procedure
performed either under local or general anaesthesia in
an outpatient setting or operating theatre at the discretion of the treating specialist as per local routine practice.
All participants will undergo endocervical curettage at
the time of their LEEP or CKC.
Following treatment, all patients will undergo the ‘Test
of Cure’ management pathway:
1. colposcopy and cervical cytology at 6 months’
postexcisional treatment
2. cervical cytology and oncogenic human papilloma
virus (HPV) typing at 12 months’ post-treatment and
then annually in accordance with the revised 2017
NCSP guidelines.4
Methods for protecting against sources of bias
A potential issue in surgical trials is performance bias. The
study setting will be tertiary level dysplasia/gynaecologic
oncology units and only the named study investigators
will be performing the excisional procedures which will
mitigate this bias to some extent. All clinical investigators
are highly experienced providers and are certified under
the Colposcopy Quality Improvement Programme in
accordance with the requirements of the Royal Australia
and New Zealand College of Obstetrics and Gynaecology.
The requirement for a single-pass specimen will also limit
surgical performance bias.
Strategies to improve adherence to intervention protocols and
any procedures for monitoring adherence
It is anticipated that participants will attend for treatment and those who do not attend will be recalled as
per routine clinical practice. Participants will be encouraged to complete the patient satisfaction questionnaire
at 6 weeks’ post-treatment by a phone call and/or email
from the site trial co-ordinators.
Outcomes
Primary outcomes: Histopathological margin status and
status of the excised specimen (single specimen or more
than one piece).
Rationale: Margin status has consistently been shown
to predict persistence and recurrence of cervical AIS.13
Disruption to the excision specimen can make orientation and interpretation of tissue margins impossible. If
there are significantly more LEEP specimens with positive
margins compared with those excised by CKC, or if there
are a greater number of specimens excised in more than
one piece compared with CKC, then it may not be appropriate to conduct a larger phase III study.
Key secondary outcomes: Frequency of early complications (pain, infection, primary and delayed haemorrhage,
readmission to hospital, return to the operating theatre),
3
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Trial design
The proposed exploratory study is a parallel group trial
with an allocation ratio of 2:1 in favour of the intervention (LEEP: CKC).
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patient satisfaction at 6 weeks’ postprocedure and costs of
treatment.
Rationale: Retrospective studies have suggested that
LEEP is associated with fewer early complications.16 17
Although the proposed study is underpowered to detect
differences in these outcomes, the purpose of their inclusion is to determine the feasibility of data collection.
Participant timelines
Figure 1 shows a consolidated standards of reporting
trials (CONSORT) flow diagram of the EXcisional
treatment Comparison for In Situ Endocervical adenocarcinoma (EXCISE) study. The schedule of enrolment,
interventions and assessments is presented in figure 2.
Following randomisation, participants will undergo the
treatment to which they are allocated (LEEP or CKC).
LEEP and CKC are usually day-case procedures. Participants will have one follow-up visit with a local study
4

co-ordinator at 6 weeks’ postprocedure. This visit may be
conducted face to face or via telephone and will involve
collection of information regarding complications postprocedure, return to hospital, general practitioner (GP)
visits and a request to complete and return the patient
satisfaction questionnaire.
We are aiming to recruit 35–40 participants for the
proposed phase I study. This sample size was determined
on a pragmatic basis (five patients recruited at each of
seven participating sites).
Sample size
The sample size for the pilot study is pragmatic. The
sample size for the potential subsequent phase III study
was estimated using a two-group test of non-inferiority
of proportions, where the primary end point is the AIS
recurrence rate at 5 years and the comparison will be
between CKC and LEEP, based on a one-sided test for
Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576
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Figure 1 Consolidated standards of reporting trials (CONSORT) flow diagram of EXCISE study. CKC, cold knife cone biopsy;
LEEP, loop electrosurgical excision procedure.
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non-inferiority. If we assume for patients in the standard
treatment arm an 8% rate of AIS recurrence at 5 years,
and a 5% non-inferiority margin (so an upper 95% confidence rate of AIS recurrence of 13% is still within the
non-inferiority margin), the total sample size needed
is 730 (365 per group). Assuming a 10% drop-out rate,
a total sample size of 810 participants (405 per group)
would need to be randomised. The one-sided type I error
Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576

is set at 5% with 80% power. Kaplan-Meier and log-rank
tests will be used to test for non-inferiority at median
follow-up of 5 years (with patient recruitment between
4 and 5 years, assuming 160–200 patients are successfully
randomised per annum). Proportional hazard models
will be used to test for differences between the two treatment groups controlling for confounding variables. All
statistical analysis will be carried out as per CONSORT
5
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Figure 2 Schedule of enrolment, interventions and assessments. AIS, adenocarcinoma in situ; BMI, body mass index; CKC,
cold knife cone biopsy; HPV, human papilloma virus; LEEP, loop electrosurgical excision procedure; STI, sexually transmitted
infection.
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Recruitment: strategies for achieving adequate participant
enrolment to reach target sample size
Several of the investigators are the clinical leads of their
local dysplasia units and triage patient referrals to their
centres. They will be ideally placed to identify potential
eligible participants. The investigators believe that it is
feasible to recruit the number of participants needed for
this phase I study based on the local incidence of cervical
AIS and enrolment rates in previous research studies.
Assignment of interventions
Allocation: Participants will be randomised to undergo
LEEP or CKC (2:1 ratio).
Generation of the allocation sequence will be by
computer-generated random numbers. The allocation
sequence will be implemented by central telephone
(interactive voice response system) and will be generated by the National Health and Medical Research
Council (NHMRC) Clinical Trials Centre, University of
Sydney.
Participants will be enrolled by the treating specialist
who will be one of the named investigators. Following
randomisation, participants will be assigned to LEEP or
CKC by a study co-ordinator at each site.
Blinding
All study investigators and participants will not be blinded
to the intervention.
Data collection, management and analysis
A case report form (CRF) will be used to record data for
each participant. The primary outcomes will be assessed
as part of routine clinical care by the reporting consultant anatomical pathologists at each site. All participating
sites will be required to complete synoptic/standardised
histopathology reports for each study participant. All specimens will undergo centralised pathology review at Royal
Prince Alfred Hospital, Camperdown, New South Wales,
Australia, by Dr Lyndal Anderson, Consultant Pathologist
and Study Investigator. Data regarding early complications will be obtained via patient medical records and at
patient follow-up visits and recorded on the CRF by the
site study co-ordinator. Patient satisfaction will be assessed
by using those aspects of the European Organization for
Research and Treatment of Cancer in-patient satisfaction
(EORTC IN-PATSAT32) which are pertinent to outpatient care, as well as additional questions on the ease of
making appointments, clinic accessibility and waiting
times.20 21 The intervention is a surgical procedure so
once performed it will not be possible for participants to
deviate from the intervention protocol. Should a participant withdraw from the study postintervention then it
may not be possible to obtain data regarding secondary
outcomes (early complications and patient satisfaction).
6

Data will only be collected with the signed permission of the participant. All questionnaires/data CRFs
will be given a unique identity number (de-identified
data) and will not include information that would allow
identification of the participant. Unique patient identification number will be generated by the interactive voice
response system (IVRS) and identified patient data will
only be available to the principal investigators at each
participating institution. Only de-identified clinical information will be used for statistical analysis and reporting.
The original study participant CRFs will be stored
securely by the relevant study site investigators. Copies
of the completed CRFs accompanied with de-identified
supporting source documents will be scanned by the
study site researchers, saved in a PDF format and these
version files will be emailed to the lead site for data entry.
The study standard operating procedures (SOP)will
be used to ensure the collection of accurate, consistent,
complete and reliable data. In addition, prior to the
study initiation at each site, an investigator meeting and
training session will be held via teleconference to prepare
both the investigators and other trial staff involved and to
standardise performance.
Safety reporting will be conducted according to trial
specific procedures. Data management will be performed
by the lead site. Accurate and reliable data collection
will be assured by 100% verification and crosscheck of
CRFs against the investigator’s records by the St John of
God (SJOG) Gynaecological Cancer Research Group.
All data will be stored in locked offices, password-protected computer files and password-protected database,
accessible only by site staff. A FileMaker Pro database
will be used for the data management, and data from
the CRFs will be entered into the database by the SJOG
Gynaecological Cancer Research Group.
Safety monitoring
An independent medical monitor (IMM) will undertake
ongoing safety monitoring throughout the trials duration
assessing serious adverse events (SAE) and suspected,
unexpected adverse reactions (SUSARs) reported by
research sites to the Trial Steering Committee (TSC).
The IMM will provide recommendations whether the
study should continue as planned or that changes should
be made to the protocol to improve safety. If matters of
major safety are identified, for example, a higher than
expected SUSARs/SAEs being reported, the IMM can
recommend that the study be postponed until matters
are clarified and resolved. Otherwise, if study participant
safety is compromised, the study must be terminated.
Data monitoring
A systematic, prioritised risk-based monitoring schedule
will be implemented by the study sponsor in accordance
with International Conference on Harmonisation Good
Clinical Practice (ICH GCP) (5.18 Monitoring) guidelines. It will encompass both on-site monitoring and
centralised remote monitoring modalities. On-site
Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576
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recommendations for non-inferiority randomised
controlled trials using intent-to-treat as well as per-protocol populations.
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Harms
The investigator is responsible for reporting all AEs and
SAEs that are observed during the study, regardless of
their relationship to treatment or their clinical significance. All AEs and SAEs that occur after surgery during
the study must be recorded in the patient’s chart and the
CRFs and followed to a satisfactory resolution or until the
local Investigator deems the patient to be stable or the
AE/SAE to have resolved. The description of the AE/SAE
will include the onset date, duration, date of resolution,
severity, seriousness, aetiology and the likelihood of relationship of the AE to study treatment. Severity of AEs will
be graded using the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0
(CTC- AE v4.0).
If an AE occurs which is not contained in the CTC-AE
v4.0, the following five-point scale will be used:
1. mild: discomfort noticed but no disruption of normal
daily activity
2. moderate: discomfort sufficient to reduce or affect
daily activity
3. severe: inability to work or perform normal daily
activity
4. life threatening: represents an immediate threat to
life
5. death.
Any AE considered serious by the local Investigator
or which meets the previous criteria must be reported
to the TSC. A CRF and SOP for SAE reporting will be
provided by the lead site. If the patient is hospitalised
because of, or during, an SAE, then a copy of the hospital
discharge summary and any other reports/results should
be emailed to the lead site (SJOG Subiaco) as soon as they
are available.
Once an investigator becomes aware that an SAE has
occurred in a study participant, they will immediately
notify the lead site via email. The SAE form must be
completed by site personnel as thoroughly as possible with
all available details of the event, signed by the investigator
Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576

(or appropriately qualified designee) and emailed to the
lead site within 24 hours of first becoming aware of the
event. The investigator will always provide an assessment
of causality at the time of the initial report.
All sites are required to submit locally occurring SAEs
to their reviewing ethics committee or site governance
office within 24 hours of first notification of SAE occurrence or according to local HREC policy.
At every study visit, patients will be asked a standard
non-leading question to obtain any medically related
changes in their well-being. They will also be asked if
they have been hospitalised, had any accidents, used any
new medications or changed concomitant medication
regimens (prescription, over-the-counter medications
and herbal supplements). In addition to patient or investigator observations, AEs will be documented from any
data collected (eg, laboratory values, physical examination findings), or other documents that are relevant to
patient safety.
The investigator’s assessment of an AE's relationship to
treatment is part of the documentation process, but it is
not a factor in determining what is or is not reported in
the study. If there is any doubt as to whether a clinical
observation is an AE, the event should be reported.
All AEs and SAEs will be followed until resolution,
until the condition stabilises, until the event is otherwise
explained, until the participant is lost to follow-up or up
to close out visit.
Once resolved, the appropriate AE/SAE CRF page(s)
will be updated. The investigator will ensure that follow-up
includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE
or SAE. This may include additional laboratory tests or
investigations, histopathological examinations or consultation with other healthcare professionals.
New or updated information for SAEs will be recorded
on the originally completed SAE form, with all changes
signed and dated by the investigator or designee. The
updated SAE form should be resent to the SJOG Gynaecological Cancer Research Group.
Auditing
Participating sites will be audited at least once during the
pilot phase by a study monitor who is an employee of the
sponsor but independent of the investigators.
Ethics and dissemination
Ethical approval for the study has been granted by the
St John of God Healthcare Human Research Ethics
Committee (reference number #1137). Important
protocol modifications will be submitted to the St John
of God Subiaco Hospital HREC as requests to amend
the approved study protocol. Informed consent will be
obtained by the participant’s treating specialist. Only the
investigators, data manager and trial co-ordinator at St
John of God Subiaco Hospital will have access to the final
7
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monitoring will verify that study participants have given
their consent to participate voluntarily, have been fully
informed of the research trial and that their rights, safety
and well-being are assured. Additionally, the monitoring
will verify that the data collected are accurate, complete
and verifiable from source documents and that the site
research personnel are conducting the trial in accordance
with the Human Research Ethics Committee (HREC)
approved study protocol and its ‘conditions of approval’.
Centralised monitoring will complement and reduce
on-site monitoring whereby reliable data and potentially
unreliable data can be distinguished, that is, omissions,
inconsistencies, incongruous or anomalous data entries
will be identified and queries can be clarified and where
applicable, corrected and resolved in a timely manner
with the relevant study sites in accordance with GCP
guidelines.
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Discussion
In contrast to cervical squamous dysplasia, the incidence
of AIS is increasing in relative and absolute terms. There
is a clear need for prospective randomised clinical trials to
determine whether LEEP is associated with similar histopathological and clinical outcomes when compared with
CKC in the investigation and management of cervical
AIS. This is the first prospective randomised study to
investigate this clinical question. Limitations of the pilot
study are its relatively short follow-up period (6 weeks)
and small sample size, which are pragmatic. The objective of the pilot study is to demonstrate the feasibility
and safety of the intervention as defined by pathological
margin status, and hence long-term outcomes of interest
including rates of cervical AIS recurrence and obstetric
complications will be endpoints in a subsequent phase
III trial. Limitations of a phase III study include those
of non-inferiority trials such as defining the acceptable
margin of AEs that would render the interventional treatment inferior, lack of a placebo group and allowing only
an indirect assessment of the efficacy of the intervention
compared with an accepted standard.
Strengths of the study include its randomised design
and attempts to minimise surgical performance bias.
If LEEP was found to be non-inferior to CKC for the
outcomes of post-treatment persistence and recurrence,
and adenocarcinoma, it could be recommended as an
appropriate treatment option for AIS in selected patients.
This would benefit women because, unlike cold knife
cone procedures, loop excision does not require hospital
admission and general anaesthesia.
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trial dataset. Participants will undergo post-trial care in
accordance with NHMRC guidelines for the follow-up
of women after treatment for cervical AIS. There are no
provisions for those who suffer harm from trial participation as any harm would be regarded as having arisen
because of routine treatment and not specifically due to
trial participation.
The investigators and sponsor do not intend to communicate results directly to participants. Results from the
study will be presented at national and international
conferences and published in a peer-reviewed scientific
journal. The authorship guidelines largely follow the rules
established by the International Committee of Medical
Journal Editors.22 The investigators do not intend to use
professional writers.

Open Access

References

1. Wilbur DC, Chieng DC, Guidos B, et al. Epithelial abnormalities:
glandular. In: Nayar R, Wilbur DC, eds. The Bethesda system for
reporting cervical cytology. Definitions, criteria and exploratory notes.
3rd ed: Springer, 2015.
2. National Cervical Screening Program. Screening to prevent cervical
cancer: guidelines for the management of asymptomatic women
with screen detected abnormalities. Canberra: National Cervical
Screening Program, 2005.
3. Massad LS, Einstein MH, Huh WK, et al. American Society for
Colposcopy and Cervical Pathology Consensus Guidelines
Conference. 2012 updated consensus guidelines for the
management of abnormal cervical cancer screening tests and cancer
precursors. J Low Genit Tract Dis 2013;17:S1–S27.
4. Anderson L, Hammond I, Pather S, et al. Cancer Council Australia
Cervical Cancer Screening Guidelines Working Party. In:Cancer
Council Australia Cervical Cancer Screening Guidelines Working
Party National Cervical Screening Program: Guidelines for the
management of screen-detected abnormalities, screening in specific
populations and investigation of abnormal vaginal bleeding. Sydney:
Cancer Council Australia. http://wiki.cancer.org.au/australia/
Guidelines:Cervical_cancer/Screening/Management_of_glandular_
abnormalities. (accessed 7 Jan 2017).
5. Krebs HB, Pastore L, Helmkamp BF. Loop electrosurgical excision
procedures for cervical dysplasia: experience in a community
hospital. Am J Obstet Gynecol 1993;169:289–95.
6. Mathevet P, Dargent D, Roy M, et al. A randomized prospective study
comparing three techniques of conization: cold knife, laser, and
LEEP. Gynecol Oncol 1994;54:175–9.
7. Azodi M, Chambers SK, Rutherford TJ, et al. Adenocarcinoma
in situ of the cervix: management and outcome. Gynecol Oncol
1999;73:348–53.
8. Denehy TR, Gregori CA, Breen JL, Thad R. Endocervical curettage,
cone margins, and residual adenocarcinoma in situ of the cervix.
Obstet Gynecol 1997;90:1–6.
9. Kennedy AW, Biscotti CV. Further study of the management of
cervical adenocarcinoma in situ. Gynecol Oncol 2002;86:361–4.

Cohen PA, et al. BMJ Open 2017;7:e017576. doi:10.1136/bmjopen-2017-017576

10. Costa S, Venturoli S, Negri G, et al. Factors predicting the outcome
of conservatively treated adenocarcinoma in situ of the uterine
cervix: an analysis of 166 cases. Gynecol Oncol 2012;124:490–5.
11. Bull-Phelps SL, Garner EI, Walsh CS, et al. Fertility-sparing surgery in
101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol
2007;107:316–9.
12. van Hanegem N, Barroilhet LM, Nucci MR, et al. Fertility-sparing
treatment in younger women with adenocarcinoma in situ of the
cervix. Gynecol Oncol 2012;124:72–7.
13. Kietpeerakool C, Khunamornpong S, Srisomboon J, et al. Predictive
value of negative cone margin status for risk of residual disease
among women with cervical adenocarcinoma in situ. Int J Gynaecol
Obstet 2012;119:266–9.
14. Baalbergen A, Helmerhorst TJ. Adenocarcinoma in situ of the uterine
cervix--a systematic review. Int J Gynecol Cancer 2014;24:1543–8.
15. Latif NA, Neubauer NL, Helenowski IB, et al. Management of
adenocarcinoma in situ of the uterine cervix: a comparison of loop
electrosurgical excision procedure and cold knife conization. J Low
Genit Tract Dis 2015;19:97-102.
16. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes
after conservative treatment for intraepithelial or early invasive
cervical lesions: systematic review and meta-analysis. Lancet
2006;367:489–98.
17. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and
other severe adverse pregnancy outcomes associated with
treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ
2008;337:a1284.
18. Munro A, Leung Y, Spilsbury K, et al. Comparison of cold knife
cone biopsy and loop electrosurgical excision procedure in the
management of cervical adenocarcinoma in situ: What is the gold
standard? Gynecol Oncol 2015;137:258–63.
19. Dalrymple C, Valmadre S, Cook A, et al. Cold knife versus laser cone
biopsy for adenocarcinoma in situ of the cervix--a comparison of
management and outcome. Int J Gynecol Cancer 2008;18:116–20.
20. Brédart A, Bottomley A, Blazeby JM, et al. An international
prospective study of the EORTC cancer in-patient satisfaction
with care measure (EORTC IN-PATSAT32). Eur J Cancer
2005;41:2120–31.
21. Pather S, Tai D, Philp S, et al. A prospective study assessing patient
satisfaction at a large tertiary gynecologic oncology/dysplasia unit.
Patient Relat Outcome Meas 2010;1:149–52.
22. http://www.icmje.org/recommendations/browse/roles-and-
responsibilities/defining-the-role-of-authors-and-contributors.html

9

BMJ Open: first published as 10.1136/bmjopen-2017-017576 on 28 August 2017. Downloaded from http://bmjopen.bmj.com/ on 29 April 2018 by guest. Protected by copyright.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the
article) 2017. All rights reserved. No commercial use is permitted unless otherwise
expressly granted.

